Back to Results
First PageMeta Content
Medicine / Pharmaceutical sciences / Food and Drug Administration / Blindness / Health / Glaucoma


Selection of Effectiveness Endpoints and Targets: What Do We Need to Show? Malik Y. Kahook, MD The Slater Family Endowed Chair in Ophthalmology Vice Chair, Clinical & Translational Research
Add to Reading List

Open Document

File Size: 136,78 KB

Share Result on Facebook

Company

Alcon Laboratories Inc. / Shape Ophthalmics LLC / P OASIS Medical Inc. / ShapeTech LLC / Allergan Inc. / GENENTECH / Glaukos Corporation / /

Facility

Canal vs Suprachoroidal / Glaucoma Service University of Colorado School / /

IndustryTerm

control devices / /

MedicalCondition

blebs / non-refractory glaucoma / Refractory glaucoma / /

MedicalTreatment

Surgery / /

Organization

FDA / World Glaucoma Association / University of Colorado School of Medicine Aurora / MDs / /

Person

Malik Y. Kahook / /

Position

The Slater Family Endowed Chair / surgeon / Professor of Ophthalmology Chief / Ophthalmology Vice Chair / /

Technology

laser / /

SocialTag